GlucoTrack amends multiple warrants and notes, removing floor price reduction terms

GlucoTrack, Inc. disclosed in a Form 8-K dated September 28, 2026 that it has been amending several sets of warrants and convertible notes tied to prior financings.

The company had previously entered a securities purchase agreement on July 14, 2026, later supplemented by an August 4, 2026 joinder, under which Glucotrack issued senior secured convertible promissory notes and common stock purchase warrants to a group of Bridge Investors.¹ Starting September 22, 2026, the company began executing amendments to those Bridge Warrants, with execution described as ongoing.¹ Separately, on September 25, 2026, in connection with the closing of the company's registered direct offering, the outstanding Bridge Notes were repaid in full.¹

GlucoTrack also amended terms tied to an August 4, 2026 private placement agreement with a single investor, under which the company had issued pre-funded warrants and common stock purchase warrants.¹ On September 22, 2026, the company and that purchaser signed an amendment to the Common Warrants, called Amendment No. 2 to Common Warrant.¹

A third financing, the September Purchase Agreement dated September 10, 2026, had produced senior secured convertible promissory notes and common stock purchase warrants issued to a group called the September Investors.¹ Starting September 22, 2026, GlucoTrack executed amendments to those notes and warrants, with the note amendments becoming effective on September 28, 2026 once all noteholders signed, according to the filing.

Across the three sets of amended warrants, the filing states that provisions allowing the Floor Price to be adjusted downward were eliminated. For the September Notes specifically, the amendment also sets the Floor Price as an absolute floor on conversion pricing and requires that any make-whole "True-Up Amount" be paid only in cash, per the filing.